share_log

HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $54

Benzinga ·  Aug 1, 2023 06:21

HC Wainwright & Co. analyst Raghuram Selvaraju maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $23 to $54.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment